Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials

Sofosbuvir is a chain-terminating nucleotide analogue inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase that is efficacious in subjects with HCV genotype 1-6 infection. Sofosbuvir resistance is primarily conferred by the S282T substitution in NS5B. NS5B sequencing and susceptibility testi...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical infectious diseases Vol. 59; no. 12; p. 1666
Main Authors:	Svarovskaia, Evguenia S, Dvory-Sobol, Hadas, Parkin, Neil, Hebner, Christy, Gontcharova, Viktoria, Martin, Ross, Ouyang, Wen, Han, Bin, Xu, Simin, Ku, Karin, Chiu, Sophia, Gane, Edward, Jacobson, Ira M, Nelson, David R, Lawitz, Eric, Wyles, David L, Bekele, Neby, Brainard, Diana, Symonds, William T, McHutchison, John G, Miller, Michael D, Mo, Hongmei
Format:	Journal Article
Language:	English
Published:	United States 15.12.2014
Subjects:	Antiviral Agents - therapeutic use Drug Resistance, Viral Female Hepacivirus - pathogenicity High-Throughput Nucleotide Sequencing Humans Male Phenotype Sofosbuvir Treatment Outcome Uridine Monophosphate - analogs & derivatives Uridine Monophosphate - therapeutic use sofosbuvir HCV NS5B polymerase GS-7977 antiviral resistance
ISSN:	1537-6591, 1537-6591
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!